6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03970798
(ClinicalTrials.gov)
May 22, 201923/5/2019A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinA Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinParkinson's DiseaseDrug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356Kyowa Kirin Co., Ltd.NULLCompleted20 Years44 YearsMale50Phase 1Japan
2JPRN-UMIN000022187
2016/05/0606/05/2016Research on Parkinson's disease pathogenesis based on analysis of caffeine absorption in patients with Parkinson's disease Parkinson's diseasePD group, 200 mg caffeine administration, qd, 1 day
Control group, 200 mg caffeine administration, qd, 1 day
Department of Neurology, Juntendo UniversityNULLComplete: follow-up complete40years-old60years-oldMale and Female20Not applicableJapan
3NCT01738178
(ClinicalTrials.gov)
April 201428/11/2012Caffeine as a Therapy for Parkinson's DiseaseCaffeine as a Therapeutic Agent in Parkinson's DiseaseParkinson's DiseaseDrug: Caffeine;Drug: PlaceboMcGill University Health CenterPontifícia Universidade Católica do Paraná;University of Calgary;University of Newfoundland and Eastern Health;University Health Network, Toronto;UBC Hospital;Movement Disorder Clinic - Deer Lodge Centre;The Ottawa HospitalCompleted45 Years75 YearsAll119Phase 3Brazil;Canada
4NCT01190735
(ClinicalTrials.gov)
August 201026/8/2010Caffeine for Motor Manifestations of Parkinson's DiseaseCaffeine for Motor Manifestations of Parkinson's Disease: An Open-Label Dose-Response Study.Parkinson's DiseaseDrug: Caffeine alkaloidRon PostumaCanadian Institutes of Health Research (CIHR)Completed18 YearsN/ABoth28Phase 2Canada
5NCT00459420
(ClinicalTrials.gov)
April 200711/4/2007Caffeine for Excessive Daytime Somnolence in Parkinson's DiseaseCaffeine for Excessive Daytime Somnolence in Parkinson's DiseaseParkinson's Disease;Excessive Daytime SomnolenceDrug: Caffeine 100-200 mg BID;Drug: placeboRon PostumaCanadian Institutes of Health Research (CIHR);University of TorontoCompleted18 YearsN/ABoth58Phase 2/Phase 3Canada